Victory Capital Management
CBIO icon

Victory Capital Management’s Crescent Biopharma CBIO Stock Holding History

Victory Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-47
Closed -$11K – 2810
2020
Q1 		$11K Buy
+47
New +$18K ﹤0.01% 3045
2019
Q4 		– Sell
-37
Closed -$16K – 2887
2019
Q3 		$16K Buy
+37
New +$23.8K ﹤0.01% 3116
2018
Q2 		– Sell
-456
Closed -$739K – 1835
2018
Q1 		$739K Buy
+456
New +$948K ﹤0.01% 1294

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Victory Capital Management's CBIO Position: Q2 2020 in Review

Victory Capital Management sold out of Crescent Biopharma (CBIO) in Q2 2020, closing a stake of 47 shares — an estimated $11K sold.

Victory Capital Management first reported a position in CBIO in Q1 2018 and held it in 3 quarters. The position peaked at $739K in Q1 2018. 87 funds tracked by Wall St. Rank hold CBIO as of Q2 2020.

  • Victory Capital Management reported no remaining Crescent Biopharma position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 47 Crescent Biopharma shares in Q2 2020, an estimated $11K.
  • Victory Capital Management first reported a position in Crescent Biopharma in Q1 2018 and held it in 3 quarters.
  • Victory Capital Management's Crescent Biopharma position peaked at $739K in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.